Skip to main content
Top
Published in: Calcified Tissue International 3/2019

01-03-2019 | Original Research

Association Between the Decline in Muscle Health and the Decline in Bone Health in Older Individuals from the SarcoPhAge Cohort

Authors: Médéa Locquet, Charlotte Beaudart, Jean-Yves Reginster, Olivier Bruyère

Published in: Calcified Tissue International | Issue 3/2019

Login to get access

Abstract

The longitudinal relationship between bone health and muscle health is scarcely explored. We aimed to explore the relationship between bone decline and muscle decline over 1 year in older individuals. We used data from the SarcoPhAge cohort, which aims to identify the consequences of sarcopenia. In this way, this study also highlights the yearly changes in muscle mass (by dual-energy absorptiometry), muscle weakness (by grip strength), and/or physical performance (by the short physical performance battery test). Measurements of areal bone mineral density (aBMD), enabling the diagnosis of osteoporosis, and bone microarchitecture (by means of the trabecular bone score) were also performed each year. A 1-year clinically relevant decline in bone and muscle health components was evidenced using the Edwards–Nunnally index. Among the 232 participants with complete data (75.5 ± 5.4 years, 57.8% women), we observed an association between a clinically relevant decline in the skeletal muscle mass index (SMI) and a decrease in aBMD (adjusted OR = 2.12 [1.14–2.51] for the spine, 2.42 [1.10–5.34] for the hip and 2.12 [1.04–5.81] for the neck), as well as a significant association between SMI and deterioration of the skeletal microarchitecture (aOR = 3.99 [2.07–7.70]). A clinically relevant decline in muscle strength was associated with a decrease in spine aBMD (aOR = 2.93 [1.21–7.12]) and hip aBMD (aOR = 3.42 [1.37–7.64]) only. The decline in muscle performance was related to the decline in bone microarchitecture only (aOR = 2.52 [1.23–5.17]). Individuals with incident sarcopenia had an approximately fivefold higher risk of concomitantly developing osteoporosis. A dynamic relationship between impaired muscle and bone health was observed, with an obvious association between the concomitant incidences of osteoporosis and sarcopenia.
Appendix
Available only for authorised users
Literature
20.
go back to reference Guralnik JM, Ferrucci L, Pieper CF et al (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A 55:M221–M231CrossRef Guralnik JM, Ferrucci L, Pieper CF et al (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A 55:M221–M231CrossRef
25.
go back to reference Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935CrossRefPubMed Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935CrossRefPubMed
27.
go back to reference Speer DC (1992) Clinically significant change: Jacobson and Truax (1991) revisited. J Consult Clin Psychol 60:402–408CrossRefPubMed Speer DC (1992) Clinically significant change: Jacobson and Truax (1991) revisited. J Consult Clin Psychol 60:402–408CrossRefPubMed
32.
go back to reference Gómez JF, Curcio C-L, Alvarado B et al (2013) Validity and reliability of the short physical performance battery (SPPB): a pilot study on mobility in the Colombian Andes. Colomb Med 44:165–171 Gómez JF, Curcio C-L, Alvarado B et al (2013) Validity and reliability of the short physical performance battery (SPPB): a pilot study on mobility in the Colombian Andes. Colomb Med 44:165–171
34.
go back to reference Kwon S, Perera S, Pahor M et al (2009) What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging 13:538–544CrossRefPubMedPubMedCentral Kwon S, Perera S, Pahor M et al (2009) What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging 13:538–544CrossRefPubMedPubMedCentral
37.
go back to reference Elkasrawy MN, Hamrick MW (2010) Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 10:56–63PubMed Elkasrawy MN, Hamrick MW (2010) Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 10:56–63PubMed
40.
go back to reference Russo CR, MD (2009) The effects of exercise on bone. Basic concepts and implications for the prevention of fractures. Clin Cases Miner Bone Metab 6:223–228PubMed Russo CR, MD (2009) The effects of exercise on bone. Basic concepts and implications for the prevention of fractures. Clin Cases Miner Bone Metab 6:223–228PubMed
Metadata
Title
Association Between the Decline in Muscle Health and the Decline in Bone Health in Older Individuals from the SarcoPhAge Cohort
Authors
Médéa Locquet
Charlotte Beaudart
Jean-Yves Reginster
Olivier Bruyère
Publication date
01-03-2019
Publisher
Springer US
Published in
Calcified Tissue International / Issue 3/2019
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-018-0503-4

Other articles of this Issue 3/2019

Calcified Tissue International 3/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine